We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
Read MoreHide Full Article
AxoGen (AXGN - Free Report) shares rallied 6.8% in the last trading session to close at $5. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.5% loss over the past four weeks.
Axogen scored a strong price increase, driven by the optimism surrounding the company’s latest presentation at the H.C. Wainwright 25th Annual Global Investment Conference held in New York on Sep 11, 2023. The company recently announced an important extension of its nerve protection platform, with the full release of Axoguard HA+ Nerve Protector. The launch of the proprietary nerve protection device expands opportunities for surgeons to treat a wider range of nerve protection challenges. This might have boosted further confidence in the stock.
This regenerative medicine company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of -1200%. Revenues are expected to be $40.1 million, up 8.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For AxoGen, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AXGN going forward to see if this recent jump can turn into more strength down the road.
AxoGen belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Stereotaxis Inc. (STXS - Free Report) , closed the last trading session 3.6% lower at $1.60. Over the past month, STXS has returned -4.1%.
Stereotaxis Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.05. Compared to the company's year-ago EPS, this represents a change of +28.6%. Stereotaxis Inc. currently boasts a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
AxoGen (AXGN - Free Report) shares rallied 6.8% in the last trading session to close at $5. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 29.5% loss over the past four weeks.
Axogen scored a strong price increase, driven by the optimism surrounding the company’s latest presentation at the H.C. Wainwright 25th Annual Global Investment Conference held in New York on Sep 11, 2023. The company recently announced an important extension of its nerve protection platform, with the full release of Axoguard HA+ Nerve Protector. The launch of the proprietary nerve protection device expands opportunities for surgeons to treat a wider range of nerve protection challenges. This might have boosted further confidence in the stock.
This regenerative medicine company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of -1200%. Revenues are expected to be $40.1 million, up 8.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For AxoGen, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AXGN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
AxoGen belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Stereotaxis Inc. (STXS - Free Report) , closed the last trading session 3.6% lower at $1.60. Over the past month, STXS has returned -4.1%.
Stereotaxis Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.05. Compared to the company's year-ago EPS, this represents a change of +28.6%. Stereotaxis Inc. currently boasts a Zacks Rank of #3 (Hold).